Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF) in pregnant women with HIV

被引：0
|
作者：
Marathe, Dhananjay [1 ]
Arora, Priyanka [1 ]
Zhang, Haeyoung [1 ]
Hindman, Jason [1 ]
Liu, Hui [1 ]
Girish, Sandhya [1 ]
Davis, Casey [1 ]
Palaparthy, Ramesh [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2024年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
26
引用
收藏
页码：19 / 19
页数：1
相关论文
共 38 条
  • [31] 24-Month (24M) effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive (TN) and treatment-experienced (TE) people living with HIV in the BICSTaR study
    Garcia-Deltoro, Miguel
    Waizmann, Michael
    Robineau, Olivier
    Wong, Alexander
    Shahar, Eduardo
    Lambert, John S.
    van Welzen, Berend
    Boffito, Marta
    Yokomaku, Yoshiyuki
    Cassidy, Tali
    Marongiu, Andrea
    Thorpe, David
    Heinzkill, Marion
    Lluis-Ganella, Carla
    Di Perri, Giovanni
    HIV MEDICINE, 2023, 24 : 23 - 23
  • [32] Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
    Kityo, Cissy
    Hagins, Debbie
    Koenig, Ellen
    Avihingsanon, Anchalee
    Chetchotisakd, Ploenchan
    Supparatpinyo, Khuanchai
    Gankina, Natalya
    Pokrovsky, Vadim
    Voronin, Evgeny
    Stephens, Jeffrey L.
    DeJesus, Edwin
    Wang, Hui
    Acosta, Rima K.
    Cao, Huyen
    Quirk, Erin
    Martin, Hal
    Makadzange, Tariro
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 (03) : 321 - 328
  • [33] Four-year outcomes from the BICSTaR study: observational analysis of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive (TN) and treatment-experienced (TE) people with HIV in Canada, France and Germany
    Wong, Alex
    Beer, Daniel
    Duvivier, Claudine
    Cordel, Hugues
    Meurer, Anja
    Thorpe, David
    Heinzkill, Marion
    Marongiu, Andrea
    Ramroth, Johanna
    Trottier, Benoit
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 73 - 74
  • [34] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age, race, sex, adherence and late presentation in a multi-country cohort study
    Trottier, B.
    Antinori, A.
    De Wet, J.
    Duvivier, C.
    Elinav, H.
    Esser, S.
    Ghosn, J.
    den Hollander, J.
    Lambert, J.
    Milinkovic, A.
    Elliott, C.
    Saifi, T.
    Haubrich, R.
    Thorpe, D.
    Marongiu, A.
    Miralles, C.
    Schellberg, S.
    van Welzen, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 69 - 70
  • [35] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
    Molina, J-M
    Gallant, J.
    Orkin, C.
    Negredo, E.
    Bhatti, L.
    Gathe, J.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Vanveggel, S.
    Opsomer, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
  • [36] 5-year outcomes of bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 cell count in two Phase 3 randomised clinical trials
    Ramgopal, Moti
    Warupa, Anson
    Baumgarten, Axel
    Berhe, Mezgebe
    Pozniak, Anton
    Orkin, Chloe
    Tiraboschi, Juan Manuel
    Hagins, Debbie
    Huang, Hailin
    Andreatta, Kristen
    Unger, Nathan
    Hindman, Jason
    Martin, Hal
    Baeten, Jared
    Osiyemi, Olayemi
    HIV MEDICINE, 2023, 24 : 33 - 33
  • [37] INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial
    Naidoo, Anushka
    Dooley, Kelly E.
    Naidoo, Kogieleum
    Padayatchi, Nesri
    Yende-Zuma, Nonhlanhla
    Perumal, Rubeshan
    Dorse, Gillian
    Boodhram, Resha
    Osuala, Emmanuella Chinonso
    BMJ OPEN, 2022, 12 (11):
  • [38] Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults
    Orkin, C.
    Molina, J-M
    Gallant, J.
    Negredo, E.
    Gathe, J.
    Eron, J.
    van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Petrovic, R.
    Opsomer, M.
    HIV MEDICINE, 2018, 19 : S32 - S32
1234